Unknown

Dataset Information

Challenges and opportunities of allogeneic donor-derived CAR T cells.


ABSTRACT:

Purpose of review

As T cells engineered with chimeric antigen receptors (CARs) are entering advanced phases of clinical trial testing with promising results, the potential implications of use in an allogeneic environment are emerging as an important consideration. This review discusses the use of allogeneic CAR therapy, the potential effects of T-cell receptor (TCR) signaling on CAR T-cell efficacy, and the potential for TCR elimination to generate an off-the-shelf product.

Recent findings

The majority of preclinical and clinical data regarding allogeneic T cells are focused on safety of their use given the potential for graft-versus-host disease (GVHD) mediated by the T-cell receptor expressed with the introduced CAR. Recent clinical trials using donor-derived CAR T cells a

SUBMITTER: Yang Y 

PROVIDER: S-EPMC4636084 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature